Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
07/2003
07/01/2003US6585970 Method for treating hypothyroidism
07/01/2003US6585968 Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
07/01/2003US6585962 Cosmetics, drugs
07/01/2003US6585957 Medicinal aerosol formulation
07/01/2003CA2123303C Icams immunoglobulin constant region soluble fusion proteins
07/01/2003CA2122338C Novel human cdc25 genes, encoded products and uses therefor
07/01/2003CA2086509C Non-cleavable soluble hybrid gp160 variant
07/01/2003CA2066387C Viral products
06/2003
06/26/2003WO2003052134A2 Oligonucleotides comprising intercalator pseudonucleotide(s) for detection of nucleic acids and mutants hereof
06/26/2003WO2003052133A2 Oligonucleotide analogues comprising intercalator pseudonucleotides
06/26/2003WO2003052132A2 Linear and hairpin oligonucleotide analogues comprising intercalator pseudonucleotides
06/26/2003WO2003052124A2 Screening method for agents useful in treating diabetes
06/26/2003WO2003052110A2 Nucleic acid nematicides
06/26/2003WO2003052100A1 Use of bard1 inhibitors for promoting cell survival
06/26/2003WO2003052096A1 Mtehod of analyzing gene expression
06/26/2003WO2003052094A2 Expression vector for the production of annexin v
06/26/2003WO2003052091A1 Growth factor modified protein matrices for tissue engineering
06/26/2003WO2003052079A2 Mutants of human insulin-like growth factor binding protein-3 (igfbp-3) and uses thereof
06/26/2003WO2003052075A2 Enzymes
06/26/2003WO2003052072A2 Antisense modulation of estrogen receptor alpha expression
06/26/2003WO2003052068A2 Mbcats as modifiers of the beta-catenin pathway and methods of use
06/26/2003WO2003052067A2 Vector mediated organelle transfection
06/26/2003WO2003052065A2 Antisense modulation of b-cell associated protein expression
06/26/2003WO2003052062A2 Antisense modulation of cd36l1 expression
06/26/2003WO2003052061A2 Novel human proteins, polynucleotides encoding them and methods of using the same
06/26/2003WO2003052048A2 Nucleic acid-associated proteins
06/26/2003WO2003051924A1 Regulation of human integrin alpha-l
06/26/2003WO2003051923A2 Novel g-protein coupled receptors and dna sequences thereof
06/26/2003WO2003051922A1 Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor
06/26/2003WO2003051921A1 Chemokine mutants acting as chemokine antagonists
06/26/2003WO2003051917A2 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
06/26/2003WO2003051915A1 A modulation protein with apoptosis coronary heart disease
06/26/2003WO2003051914A2 Ides, an igg-degrading enzyme of streptococcus pyogenes
06/26/2003WO2003051912A2 Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
06/26/2003WO2003051911A2 Gmg-5 polynucleotides and polypeptides and uses thereof
06/26/2003WO2003051910A2 Inhibitors of hepatitis c virus protease
06/26/2003WO2003051909A2 Process for the manufacture of pharmaceutically acceptable salts of a compound
06/26/2003WO2003051901A2 Pseudonucleotide comprising an intercalator
06/26/2003WO2003051848A2 Imidazolidineacetic acid derivatives
06/26/2003WO2003051837A2 Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr)
06/26/2003WO2003051835A2 Methods and compositions for the inhibition of viral release
06/26/2003WO2003051831A2 Protease inhibitors of the coagulation cascade isolated from dysidea sponges
06/26/2003WO2003051797A2 Small-molecule inhibitors of interleukin-2
06/26/2003WO2003051401A2 Stabilised mrna tumour vaccine
06/26/2003WO2003051396A1 Treating vascular disease by inhibiting myeloid differentiation factor 88
06/26/2003WO2003051393A2 Enzymatic cleavable reagents for specific delivery to disease sites
06/26/2003WO2003051391A1 Method of treating obesity, overweight, diabetes, or fluctuations in blood insuline or glucose levels
06/26/2003WO2003051390A1 Use of a polypeptide for treatment of pruritus in animals
06/26/2003WO2003051389A2 Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
06/26/2003WO2003051388A2 Pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
06/26/2003WO2003051387A1 Remedies and/or preventives for conformational diseases
06/26/2003WO2003051386A1 Glucoset agonists and antagonists for use in the treatment of metabolic disorders
06/26/2003WO2003051385A1 Pharmaceutical formulation comprising cyclosporin and use thereof
06/26/2003WO2003051384A1 Method for treating cervical cancer
06/26/2003WO2003051383A2 Use of hmgb proteins and nucleic acids that code therefor
06/26/2003WO2003051380A2 Compositions containeing curcuma extracts for the treatment of neurocerebrovascular disorders
06/26/2003WO2003051377A1 Method for preparing fetuin and polypeptide to induce apoptosis
06/26/2003WO2003051374A2 SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
06/26/2003WO2003051371A1 Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances
06/26/2003WO2003051347A1 Use of urokinase receptor antagonists to modulate ischemiareperfusion injury
06/26/2003WO2003051345A2 Use of digestive enzyme mixtures for treating pathological bacterial overgrowth of the small intestine of mammals and humans
06/26/2003WO2003051344A1 Methods of inducing ovulation_using a non-polypeptide camp level modulator
06/26/2003WO2003051334A2 Pharmaceutical composition comprising an oil/water/oil double microemulsion incorporated into a solid support
06/26/2003WO2003051331A1 Methods for treating wounds using melanin and related substances
06/26/2003WO2003051328A1 Solid dose micro implant
06/26/2003WO2003051313A2 Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes
06/26/2003WO2003051312A2 E2f and cancer therapy
06/26/2003WO2003051309A2 Antisense modulation of abc transporter mhc 1 expression
06/26/2003WO2003051308A2 Antisense modulation of tfap2c expression
06/26/2003WO2003051296A2 Improved skin barrier function and cohesion through enhanced stratum corneum acidification
06/26/2003WO2003051287A2 Topical compositions and methods for treatment of adverse effects of ionizing radiation
06/26/2003WO2003051285A2 Therapeutic anti-hiv (iv9) compounds
06/26/2003WO2003051281A2 Composition and method to treat viral bacterial and parasitic infections and infestations
06/26/2003WO2003051278A2 Nanoparticle delivery vehicle
06/26/2003WO2003051272A2 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR GnRH-I AND GnRH-II MODULATION OF T-CELL ACTIVITY, ADHESION, MIGRATION AND EXTRAVASATION
06/26/2003WO2003051180A2 METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS USING 252, 304, 19870, 14717, 9941, 19310 and 17832
06/26/2003WO2003035678A3 Sperm factor sequences
06/26/2003WO2003027235A8 Afap sequences, polypeptides, antibodies and methods
06/26/2003WO2003020304A3 Inflammation modulatory compound comprising an endomorphin
06/26/2003WO2003020223A3 A cancer treatment system
06/26/2003WO2003020005A3 Lp mammalian proteins; related reagents
06/26/2003WO2003014153A8 Cellular virus receptors and methods of use.
06/26/2003WO2003000721A3 Mycobacterial antigens expressed under low oxygen tension
06/26/2003WO2002094860A3 Dimerized t-cell receptor fragment, its compositions and use
06/26/2003WO2002094202A3 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
06/26/2003WO2002087606A3 Modulators of the hypocretin system and methods of screening therefor
06/26/2003WO2002079240A3 Intimins for the prevention or treatment of infections: i
06/26/2003WO2002070696A3 Cd109 nucleic acid molecules polypeptides and methods of use
06/26/2003WO2002064781A3 Regulation of amyloid precursor protein expression by modification of abc transporter expression or activity
06/26/2003WO2002064766A3 Bax-responsive genes for drug target identification in yeast and fungi
06/26/2003WO2002062404A3 Closure of ruptured tissue and bulking of tissue
06/26/2003WO2002047611A8 Cddo-compounds and combination therapies thereof
06/26/2003WO2002046385A3 Enzymes
06/26/2003WO2002044406A3 Projection against mycobacterial infections
06/26/2003WO2002044340A3 Novel nucleic acids and polypeptides
06/26/2003WO2002042329A3 Compositions and methods relating to prostate specific genes and proteins
06/26/2003WO2002018608A3 Methods for enhancing the efficacy of cancer therapy
06/26/2003WO2002016597A3 Lipid metabolism enzymes
06/26/2003WO2002016591A3 Human transporter family members and uses thereof
06/26/2003WO2002016412A3 Binding polypeptides for b lymphocyte stimulator protein (blys)
1 ... 1820 1821 1822 1823 1824 1825 1826 1827 1828 1829 1830 1831 1832 1833 1834 1835 1836 1837 1838 1839 1840 ... 3163